News

Conference Coverage

Radiolabeled 89Zr-DFO-girentuximab PET/CT Imaging Accurately Identifies Clear Cell Renal Cell Carcinoma

02/22/2023

Allison Casey

According to phase 3 results presented at the 2023 ASCO GU Cancers Symposium, radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) PET/CT was able to accurately identify clear cell renal cell carcinoma.

According to phase 3 results...

02/22/2023

Oncology

Conference Coverage

Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma

02/21/2023

Allison Casey

According to 3-year follow-up data presented at the 2023 ASCO GU Symposium, nivolumab plus cabozantinib continues to demonstrate benefits in survival and response for patients with advanced renal cell carcinoma, compared with sunitinib.

According to 3-year follow-up...

02/21/2023

Oncology

News

Bevacizumab Plus Sunitinib for Patients With Advanced Renal Cell Carcinoma

01/26/2023

Allison Casey

In a phase 1/2 study, the addition of bevacizumab to a sunitinib on/off regimen demonstrated anti-tumor activity for patients with advanced renal cell carcinoma.

In a phase 1/2 study, the...

01/26/2023

Oncology

News

Nivolumab, Ipilimumab, and Cabozantinib Triplet Therapy Demonstrates Clinical Activity for Patients With Advanced Renal Cell Carcinoma

12/01/2022

Allison Casey

According to results from a discontinued arm of a phase 3 trial, the immunotherapy triplet regimen of nivolumab, ipilimumab, and cabozantinib demonstrated clinical activity in previously untreated patients with advanced renal cell carcinoma.

According to results from a...

12/01/2022

Oncology

News

Frontline Axitinib Plus Pembrolizumab vs Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma

10/31/2022

Findings from a comparative effectiveness analysis show no statistically significant difference in survival outcomes between axitinib plus pembrolizumab vs ipilimumab plus nivolumab for the frontline treatment of patients with metastatic...

Findings from a comparative...

10/31/2022

Oncology

News

Sapanisertib With or Without TAK-117 vs Everolimus for Clear Cell Renal Cell Carcinoma

10/27/2022

In a phase 2 study, sapanisertib with or without TAK-177 demonstrated lower tolerability with no improvement in efficacy vs everolimus for patients with advanced clear cell renal cell carcinoma.

In a phase 2 study, sapanisertib...

10/27/2022

Oncology

Axel Bex, MD, Netherlands Cancer Institute

Videos

Adjuvant Atezolizumab vs Placebo Following Nephrectomy for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

10/19/2022

Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.

Axel Bex, MD, reviews results...

10/19/2022

Oncology

News

Adjuvant Pembrolizumab Demonstrates Durable Survival Benefit for Post-Nephrectomy Patients With Clear Cell Renal Cell Carcinoma

09/30/2022

Allison Casey

Follow-up analysis of the phase 3 KEYNOTE-564 trial demonstrates a durable benefit from pembrolizumab in disease-free survival for patients who had undergone nephrectomy for clear cell renal cell carcinoma.

Follow-up analysis of the phase...

09/30/2022

Oncology

Conference Coverage

Perioperative Nivolumab Shows No Benefit to Recurrence-Free Survival for Patients With Renal Cell Carcinoma

09/10/2022

Allison Casey

Perioperative nivolumab did not improve recurrence-free survival for patients with renal cell carcinoma at high risk for recurrence, according to phase 3 study results presented at the 2022 ESMO Congress.

Perioperative nivolumab did not...

09/10/2022

Oncology

News

First-Line Nivolumab Plus Cabozantinib Yields Superior Efficacy vs Sunitinib for Renal Cell Carcinoma

09/06/2022

Allison Casey

Final overall survival analysis from the phase 3 CheckMate 9ER trial demonstrate improved efficacy of nivolumab plus cabozantinib compared to sunitinib for the first-line treatment of patients with advanced renal cell carcinoma.

Final overall survival analysis...

09/06/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology